< 31 mL per min) and with hepatic impairment, a dose of 5 mg once a day is recommended {01} . Usual adult prescribing limits 10 mg a day {01} . Usual pediatric dose Antihistaminic (H 1 -receptor) 1 Children up to 2 years of age: Safety and efficacy have not been established. {26} {46} Children 2 to 6 years of age: Oral, 2.5 mg once a day. The dosage may be increased to a maximum daily dose of 5 mg, given as 5 mg once a day or 2.5 mg every 12 hours. {26} {46} Children 6 years of age and older: Oral, 5 or 10 mg once a day. {01} {26} {46} Note: The dosage should be decreased in patients who have reduced renal function (creatinine clearance of 11–31 mL per minute) or hepatic function impairment. In patients up to 6 years of age with renal or hepatic dysfunction, cetirizine use is not recommended. For children 6 years of age and older, the lower dosage of 5 mg once a day should be used. {26} {46} Usual geriatric dose See Usual adult and adolescent dose {01} {26} . Strength(s) usually available U.S.— 5 mg per 5 mL (Rx) [ Zyrtec (alcohol and dye free)] Canada— Not commercially available. Packaging and storage: Store between 15 and 30 °C (59 and 86 °F), in a tight container, unless otherwise specified by the manufacturer. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. CETIRIZINE HYDROCHLORIDE TABLETS Usual adult and adolescent dose Antihistaminic (H 1 -receptor) See Cetirizine Syrup . Usual pediatric dose Antihistaminic (H 1 -receptor) See Cetirizine Syrup . Usual geriatric dose See Cetirizine Syrup . Strength(s) usually available U.S.— 5 mg (Rx) [ Zyrtec (dye free)] 10 mg (Rx) [ Zyrtec (dye free)] Canada— 10 mg (OTC) [ Reactine {29} ] [ Zyrtec {28} ] Packaging and storage: Store between 15 and 30 °C (59 and 86 °F), in a well-closed container, unless otherwise specified by manufacturer. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. CHLORPHENIRAMINE Summary of Differences Pharmacology/pharmacokinetics: Chemical group—Propylamine derivative. pKa—9.2. Protein binding—72%. Half-life—14 to 25 hours. Time to peak concentration—2 to 6 hours. Time to peak effect—6 hours. Duration of action—4 to 8 hours. Side/adverse effects: Sedative effects less pronounced; no paradoxical reaction. Oral Dosage Forms CHLORPHENIRAMINE MALEATE EXTENDED-RELEASE CAPSULES USP Usual adult and adolescent dose Antihistaminic (H 1 -receptor) Oral, 8 or 12 mg every eight to twelve hours as needed. Usual pediatric dose Antihistaminic (H 1 -receptor) Children up to 12 years of age: Use is not recommended. Children 12 years of age and over: Oral, 8 mg every twelve hours as needed. Usual geriatric dose See Usual adult and adolescent dose . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 8 mg (Rx) [ Telachlor ][Generic] 8 mg (OTC)[Generic] 12 mg (Rx) [ Telachlor ][Generic] 12 mg (OTC) [ Teldrin ][Generic] Canada— Not commercially available. Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a tight container. Auxiliary labeling: • Swallow capsules whole. • May cause drowsiness. • Avoid alcoholic beverages. CHLORPHENIRAMINE MALEATE SYRUP USP Usual adult and adolescent dose Antihistaminic (H 1 -receptor) Oral, 4 mg every four to six hours as needed. Usual adult prescribing limits Up to 24 mg daily. Usual pediatric dose Antihistaminic (H 1 -receptor) Oral, 87.5 mcg (0.0875 mg) per kg of body weight or 2.5 mg per square meter of body surface every six hours as needed; or for • Children up to 6 years of age: Use is not recommended. • Children 6 to 12 years of age: Oral, 2 mg three or four times a day as needed, not to exceed 12 mg per day. Usual geriatric dose See Usual adult and adolescent dose . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 1 mg per 5 mL (OTC) [ PediaCare Allergy Formula ] 2 mg per 5 mL (OTC) [ Aller-Chlor (alcohol 7%)] [ Chlor-Trimeton ( alcohol 5%)][Generic] Canada— 2.5 mg per 5 mL (OTC) [ Chlor-Tripolon (alcohol 7%)] Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a tight, light-resistant container. Protect from freezing. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. CHLORPHENIRAMINE MALEATE TABLETS USP Usual adult and adolescent dose See Chlorpheniramine Maleate Syrup USP . Usual pediatric dose See Chlorpheniramine Maleate Syrup USP . Usual geriatric dose See Chlorpheniramine Maleate Syrup USP . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 4 mg (Rx) [ Phenetron (scored)][Generic] 4 mg (OTC) [ Aller-Chlor ] [ Chlorate ] [ Chlor-Trimeton ( scored)] [ Chlor-Trimeton Allergy ] [ Gen-Allerate ][Generic] Canada— 4 mg (OTC) [ Chlor-Tripolon (scored)] [ Novo-Pheniram (scored)] Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a tight container. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. CHLORPHENIRAMINE MALEATE TABLETS (CHEWABLE) USP Usual adult and adolescent dose See Chlorpheniramine Maleate Syrup USP . Usual pediatric dose See Chlorpheniramine Maleate Syrup USP . Usual geriatric dose See Chlorpheniramine Maleate Syrup USP . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 2 mg (OTC) [ Chlo-Amine ] Canada— Not commercially available. Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a tight container. Auxiliary labeling: • Chew before swallowing. • May cause drowsiness. • Avoid alcoholic beverages. CHLORPHENIRAMINE MALEATE EXTENDED-RELEASE TABLETS Usual adult and adolescent dose See Chlorpheniramine Maleate Extended-release Capsules USP . Usual pediatric dose See Chlorpheniramine Maleate Extended-release Capsules USP . Usual geriatric dose See Chlorpheniramine Maleate Extended-release Capsules USP . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 8 mg (Rx) [ Phenetron ][Generic] 8 mg (OTC) [ Chlor-Trimeton Repetabs ][Generic] 12 mg (Rx) [ Phenetron (sugar-coated)][Generic] 12 mg (OTC) [ Chlor-Trimeton Repetabs (sugar-coated)][Generic] Canada— 12 mg (OTC) [ Chlor-Tripolon ] Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), in a well-closed container, unless otherwise specified by manufacturer. Auxiliary labeling: • Swallow tablets whole. • May cause drowsiness. • Avoid alcoholic beverages. Parenteral Dosage Forms CHLORPHENIRAMINE MALEATE INJECTION USP Usual adult and adolescent dose Antihistaminic (H 1 -receptor) Intramuscular, intravenous, or subcutaneous, 5 to 40 mg administered as a single dose as needed. Usual adult prescribing limits Up to 40 mg daily. Usual pediatric dose Antihistaminic (H 1 -receptor) Subcutaneous, 87.5 mcg (0.0875 mg) per kg of body weight or 2.5 mg per square meter of body surface every six hours as needed. Note: Premature and full-term neonates—Use is not recommended. Usual geriatric dose See Usual adult and adolescent dose . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 10 mg per mL (Rx)[Generic] Canada— 10 mg per mL (Rx) [ Chlor-Tripolon ] Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Protect from light. Protect from freezing. Additional information: The 10-mg-per-mL solution may be administered intravenously, intramuscularly, or subcutaneously. CLEMASTINE Summary of Differences Pharmacology/pharmacokinetics: Chemical group—Ethanolamine derivative. Other actions/effects—Greater anticholinergic activity. Time to peak concentration—2 to 4 hours. Time to peak effect—5 to 7 hours. Duration of action—12 hours. Oral Dosage Forms CLEMASTINE FUMARATE SYRUP Usual adult and adolescent dose Antihistaminic (H 1 -receptor) Oral, 1.34 mg two times a day or 2.68 mg one to three times a day as needed. Note: Clemastine is indicated for dermatologic conditions at the 2.68-mg dosage level only. Usual adult prescribing limits Up to 8.04 mg daily. Usual pediatric dose Antihistaminic (H 1 -receptor) Children up to 6 years of age: Dosage has not been established. Children 6 to 12 years of age: Oral, 670 mcg (0.67 mg) to 1.34 mg two times a day, not to exceed 4.02 mg per day. Note: Clemastine is indicated for dermatologic conditions at the 1.34-mg dosage level only. Usual geriatric dose See Usual adult and adolescent dose . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 0.67 mg per 5 mL (Rx) [ Tavist (alcohol 5.5%)][Generic] Canada— 0.67 mg per 5 mL (OTC) [ Tavist (alcohol 6.1%)] Packaging and storage: Store below 25 °C (77 °F), preferably between 15 and 25 °C (59 and 77 °F), in a well-closed container, unless otherwise specified by manufacturer. Protect from freezing. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. CLEMASTINE FUMARATE TABLETS USP Usual adult and adolescent dose See Clemastine Fumarate Syrup . Note: Clemastine is indicated for dermatologic conditions at the 2.68-mg dosage level only. Usual pediatric dose See Clemastine Fumarate Syrup. Note: Clemastine is indicated for dermatologic conditions at the 1.34-mg dosage level only. Usual geriatric dose See Clemastine Fumarate Syrup . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 1.34 mg (OTC) [ Contac 12 Hour Allergy ] [ Tavist-1 (scored)][Generic] 2.68 mg (Rx) [ Tavist (scored)][Generic] Canada— 1 mg (base) (OTC) [ Tavist (scored)] Packaging and storage: Store between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a tight, light-resistant container. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. CYPROHEPTADINE Summary of Differences Indications: Also indicated in cold urticaria and used as an appetite stimulant in adults and children. Pharmacology/pharmacokinetics: Chemical group—Piperidine derivative. pKa—9.3. Other actions/effects—Serotonin antagonist. Duration of action—8 hours. Precautions: Laboratory value alterations: May increase serum amylase and serum prolactin concentrations when administered with thyrotropin-releasing hormone. Side/adverse effects: Potential for blood dyscrasias; no paradoxical reaction. Oral Dosage Forms Note: Bracketed uses in the Dosage Forms section refer to categories of use and/or indications that are not included in U.S. product labeling. CYPROHEPTADINE HYDROCHLORIDE SYRUP USP Usual adult and adolescent dose Antihistaminic (H 1 -receptor) Oral, initially 4 mg every eight hours, the dosage being increased as needed. For most patients the therapeutic range is 4 to 20 mg a day. However, doses up to 32 mg a day have been used occasionally. {48} [Vascular headache suppressant ] Initial: Oral, 4 mg at the start of the attack, repeated after thirty minutes if necessary. {48} Maintenance: Oral, 4 mg every four to six hours. {48} Usual adult prescribing limits 32 mg per day {48} Usual pediatric dose Antihistaminic (H 1 -receptor) • Children 2 to 6 years of age: Oral, 2 mg every eight to twelve hours as needed, not to exceed 12 mg per day {48} . • Children 7 to 14 years of age: Oral, 2 mg every six to eight hours as needed, not to exceed 16 mg per day {48} . Note: Premature and full-term neonates—Use is not recommended. Usual geriatric dose See Usual adult and adolescent dose . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— Not commercially available. Canada— 2 mg per 5 mL (OTC) [ Periactin (alcohol 5%) {48} ] Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), {48} unless otherwise specified by manufacturer. Store in a tight container. {48} Protect from freezing. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. CYPROHEPTADINE HYDROCHLORIDE TABLETS USP Usual adult and adolescent dose Antihistaminic (H 1 -receptor) Oral, initially 4 mg every eight hours, the dosage being increased as needed. For most patients the therapeutic range is 4 to 20 mg a day. However, doses up to 32 mg a day have been used occasionally. {02} [Appetite stimulant] Oral, 4 mg three times a day with meals. Note: Treatment period to promote weight gain should not exceed six months. [Vascular headache suppressant ] Initial: Oral, 4 mg at the start of the attack, repeated after thirty minutes if necessary. Maintenance: Oral, 4 mg every four to six hours. Usual adult prescribing limits 500 mcg (0.5 mg) per kg of body weight daily {02} . Usual pediatric dose Antihistaminic (H 1 -receptor) Oral, 125 mcg (0.125 mg) per kg of body weight or 4 mg per square meter of body surface, every eight to twelve hours as needed or for • Children 2 to 6 years of age: Oral, 2 mg every eight to twelve hours as needed, not to exceed 12 mg per day {02} . • Children 7 to 14 years of age: Oral, 4 mg every eight to twelve hours as needed, not to exceed 16 mg per day {02} . [Appetite stimulant] Children 2 to 6 years of age: Oral, initially 2 mg two or three times a day with meals. The dosage may be increased, if necessary, but not to exceed 8 mg a day. Children 7 to 14 years of age: Oral, initially 2 mg three or four times a day with meals. The usual maintenance dose is 4 mg two or three times a day. The dosage may be increased, if necessary, but not to exceed 16 mg a day. Note: Premature and full-term neonates—Use is not recommended. Treatment period to promote weight gain should not exceed 3 months. Usual geriatric dose See Usual adult and adolescent dose . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 4 mg (Rx) [ Periactin (scored) {02} ][Generic] Canada— 4 mg (OTC) [ Periactin (scored) {48} ] Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), {48} unless otherwise specified by manufacturer. Store in a well-closed container. {02} Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. DESLORATADINE Summary of Differences Indications: Used for treatment of allergic rhinitis and chronic idiopathic urticaria. {51} {52} Pharmacology/pharmacokinetics: Chemical group—Piperidine derivative; metabolite of loratadine. {51} {52} Molecular weight—310.8 {51} {52} pKa—Pyridine functional group; 4.2 {52} pKa—Piperidine functional group; 9.7 {52} Protein binding—desloratadine 82 to 87% ; 3-hydroxydesloratadine (active metabolite): 85 to 89% {51} Half-life—27 hours. {51} {52} Onset of action—Histamine skin wheal studies—within one hour. {51} Time to peak concentration—approximately 3 hours. {51} {52} Duration of action—Histamine skin wheal studies—up to 24 hours. {51} Precautions: Medical considerations/contraindications—hepatic and renal impairment cause increases in pharmacokinetic parameters requiring dosage adjustments. {51} Side/adverse effects: May cause anaphylaxis, dry mouth, dysmenorrhea, dyspepsia, dyspnea, fatigue, edema, headache, myalgia, nausea, pharyngitis, pruritus, rash, somnolence, tachycardia or urticaria. {51} Oral Dosage Forms DESLORATADINE TABLETS Usual adult and adolescent dose Rhinitis, allergic (treatment) Oral, 5 mg once daily. {51} {52} Urticaria, idiopathic, chronic (treatment) Oral, 5 mg once daily. {51} {52} Note: In patients with liver or renal impairment, U.S. prescribing information recommends a starting dose of Oral, 5 mg every other day. {51} Usual Pediatric Dose Safety and efficacy have not been established. {51} {52} Geriatric Dose See Usual adult and adolescent dose. {51} {52} Strength(s) usually available U.S.— 5 mg (Rx) [ Clarinex ] {51} Canada— 5 mg (Rx) [ Aerius ] {52} Packaging and storage: Store between 2 and 25 °C (36 and 77 °F). Avoid exposure at or above 30 °C (86 °F). Heat sensitive. Protect from moisture. {51} Note: Canadian product information states to store between 15 and 30 °C. {52} Auxiliary labeling: • Do not use if you are breast-feeding. Contact your doctor or pharmacist. DEXCHLORPHENIRAMINE Summary of Differences Pharmacology/pharmacokinetics: Chemical group—Propylamine derivative. Duration of action—4 to 8 hours. Side/adverse effects: Potential for blood dyscrasias; thickening of mucus less pronounced. Oral Dosage Forms DEXCHLORPHENIRAMINE MALEATE SYRUP USP Usual adult and adolescent dose Antihistaminic (H 1 -receptor) Oral, 2 mg every four to six hours as needed. Usual pediatric dose Antihistaminic (H 1 -receptor) Children up to 12 years of age: Oral, 150 mcg (0.15 mg) per kg of body weight or 4.5 mg per square meter of body surface per day, in four divided doses or for • Children 2 to 5 years of age: Oral, 500 mcg (0.5 mg) every four to six hours as needed. • Children 5 to 12 years of age: Oral, 1 mg every four to six hours as needed. Note: Premature and full-term neonates—Use is not recommended. Usual geriatric dose See Usual adult and adolescent dose . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 2 mg per 5 mL (Rx) [ Polaramine (alcohol 6%)] Canada— 2 mg per 5 mL (OTC) [ Polaramine (alcohol 5%)] Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a tight container. Protect from light. Protect from freezing. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. DEXCHLORPHENIRAMINE MALEATE TABLETS USP Usual adult and adolescent dose See Dexchlorpheniramine Maleate Syrup USP . Usual pediatric dose See Dexchlorpheniramine Maleate Syrup USP . Usual geriatric dose See Dexchlorpheniramine Maleate Syrup USP . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 2 mg (Rx) [ Polaramine ] Canada— 2 mg (OTC) [ Polaramine ] Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a tight container. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. DEXCHLORPHENIRAMINE MALEATE EXTENDED-RELEASE TABLETS Usual adult and adolescent dose Antihistaminic (H 1 -receptor) Oral, 4 or 6 mg every eight to twelve hours as needed. Usual pediatric dose Use is not recommended. Usual geriatric dose See Usual adult and adolescent dose . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 4 mg (Rx) [ Dexchlor ] [ Polaramine Repetabs (sugar-coated)][Generic] 6 mg (Rx) [ Dexchlor ] [ Polaramine Repetabs (sugar-coated)][Generic] Canada— 6 mg (OTC) [ Polaramine Repetabs ] Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), in a well-closed container, unless otherwise specified by manufacturer. Auxiliary labeling: • Swallow tablets whole. • May cause drowsiness. • Avoid alcoholic beverages. DIMENHYDRINATE Summary of Differences Category: Also indicated as an antiemetic and antivertigo agent. Pharmacology/pharmacokinetics: Chemical group—Ethanolamine derivative. Other actions/effects—Greater anticholinergic activity. Duration of action—3 to 6 hours. Precautions: Drug interactions and/or related problems—May decrease emetic response to apomorphine. Medical considerations/contraindications—May impede diagnosis of appendicitis; may obscure signs of overdose. Additional Dosing Information See also General Dosing Information . When dimenhydrinate is used for prophylaxis of motion sickness, it should be taken at least 30 minutes, and preferably 1 or 2 hours, before exposure to conditions that may precipitate motion sickness. For parenteral dosage form only • Do not administer intra-arterially. Oral Dosage Forms DIMENHYDRINATE EXTENDED-RELEASE CAPSULES Usual adult and adolescent dose Antiemetic or Antivertigo agent Oral, 1 capsule every twelve hours. Usual pediatric dose Use is not recommended. Usual geriatric dose See Usual adult and adolescent dose . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— Not commercially available. Canada— 75 mg (25 mg for immediate release and 50 mg for extended release) (OTC) [ Gravol L/A {27} ] Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), in a well-closed container, unless otherwise specified by manufacturer. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. DIMENHYDRINATE ORAL SOLUTION Usual adult and adolescent dose Antiemetic or Antivertigo agent Oral, 50 to 100 mg every four to six hours. {10} {27} Usual adult prescribing limits 400 mg per 24 hours. {10} {27} Usual pediatric dose Antiemetic or Antivertigo agent Children 2 to 6 years of age: Oral, 12.5 to 25 mg every six to eight hours as needed, not to exceed 75 mg per day {10} {27} . Children 6 to 12 years of age: Oral, 25 to 50 mg every six to eight hours as needed, not to exceed 150 mg per day {10} {27} . Note: Premature and full-term neonates—Use is not recommended. Usual geriatric dose See Usual adult and adolescent dose . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 12.5 mg per 5 mL (OTC)[Generic] {31} Canada— 15 mg per 5 mL (OTC) [ Gravol Liquid {27} ( alcohol-free)] Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a well-closed container. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. DIMENHYDRINATE SYRUP USP Usual adult and adolescent dose See Dimenhydrinate Oral Solution . Usual adult prescribing limits See Dimenhydrinate Oral Solution . Usual pediatric dose See Dimenhydrinate Oral Solution . Note: Premature and full-term neonates—Use is not recommended. Usual geriatric dose See Dimenhydrinate Oral Solution . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 12.5 mg per 5 mL (OTC) [ Dramamine ][Generic] Canada— 15 mg per 5 mL (OTC) [ PMS-Dimenhydrinate {32} ] Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a tight container. Protect from freezing. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. DIMENHYDRINATE TABLETS USP Usual adult and adolescent dose See Dimenhydrinate Oral Solution . Usual adult prescribing limits See Dimenhydrinate Oral Solution . Usual pediatric dose See Dimenhydrinate Oral Solution . Note: Premature and full-term neonates—Use is not recommended. Usual geriatric dose See Dimenhydrinate Oral Solution . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 50 mg (OTC) [ Calm X (scored)] [ Dramamine (scored)] [ Triptone Caplets ][Generic] Canada— 15 mg (OTC) [ Gravol Filmkote {27} ] 25 mg (OTC) [ Gravol Filmkote {27} (Junior Strength )] 50 mg (OTC) [ Apo-Dimenhydrinate ] [ Gravol Filmkote {27} ] [ PMS-Dimenhydrinate ] [ Traveltabs ] Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a well-closed container. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. DIMENHYDRINATE TABLETS (CHEWABLE) USP Usual adult and adolescent dose See Dimenhydrinate Oral Solution . Usual adult prescribing limits See Dimenhydrinate Oral Solution . Usual pediatric dose See Dimenhydrinate Oral Solution . Note: Premature and full-term neonates—Use is not recommended. Usual geriatric dose See Dimenhydrinate Oral Solution . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 50 mg (OTC) [ Dramamine (scored)] Canada— 15 mg (OTC) [ Gravol {27} ] 50 mg (OTC) [ Gravol {27} ] Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a well-closed container. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. Parenteral Dosage Forms DIMENHYDRINATE INJECTION USP Usual adult and adolescent dose Antiemetic or Antivertigo agent Intramuscular, 50 mg repeated every four hours as needed. Intravenous, 50 mg in 10 mL of 0.9% sodium chloride injection, administered slowly over a period of at least two minutes, repeated every four hours as needed. Usual pediatric dose Antiemetic or Antivertigo agent Intramuscular, 1.25 mg per kg of body weight or 37.5 mg per square meter of body surface, every six hours as needed, not to exceed 300 mg per day. Intravenous, 1.25 mg per kg of body weight or 37.5 mg per square meter of body surface, in 10 mL of 0.9% sodium chloride injection, administered slowly over a period of at least two minutes, every six hours as needed, not to exceed 300 mg per day. Note: Premature and full-term neonates—Use is not recommended. Usual geriatric dose See Usual adult and adolescent dose . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 50 mg per mL (Rx) [ Dinate ] [ Dramanate ] [ Hydrate ][Generic] Canada— 10 mg per mL (Rx) [ Gravol I/V {27} {30} (for intravenous administration only) ( ethyl alcohol)] 50 mg per mL (Rx) [ Gravol I/M {27} {30} (for intramuscular administration) ( methylparaben) (propylene glycol) (propylparaben {27} )] Note: The 50-mg-per-mL concentration is intended for intramuscular use. To use this concentration for intravenous administration, the solution must be further diluted at a ratio of at least 1:10 (10 mL of diluent for each 1 mL of dimenhydrinate) with a compatible intravenous solution, such as sterile saline or 5% dextrose in water. {27} Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Protect from freezing. Rectal Dosage Forms DIMENHYDRINATE SUPPOSITORIES Usual adult and adolescent dose Antiemetic or Antivertigo agent Rectal, 50 to 100 mg every six to eight hours as needed. Usual pediatric dose Antiemetic or Antivertigo agent Children up to 6 years of age: Dosage has not been established. Children 6 to 8 years of age: Rectal, 12.5 to 25 mg every eight to twelve hours as needed. Children 8 to 12 years of age: Rectal, 25 to 50 mg every eight to twelve hours as needed. Children 12 years of age and over: Rectal, 50 mg every eight to twelve hours as needed. Usual geriatric dose See Usual adult and adolescent dose . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— Not commercially available. Canada— 25 mg (OTC) [ Gravol ] Packaging and storage: Store between 8 and 15 °C (46 and 59 °F), in a well-closed container, unless otherwise specified by manufacturer. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. Note: When dispensing, include patient instructions. DIPHENHYDRAMINE Summary of Differences Category: Also indicated as an antidyskinetic, antiemetic, antitussive (syrup only), antivertigo agent, and a sedative-hypnotic. Pharmacology/pharmacokinetics: Chemical group—Ethanolamine derivative. pKa—9. Other actions/effects—Greater anticholinergic activity. Protein binding—98 to 99%. Half-life—1 to 4 hours. Time to peak concentration—1 to 4 hours. Duration of action—6 to 8 hours. Precautions: Drug interactions and/or related problems—May decrease emetic response to apomorphine. Medical considerations/contraindications—May impede diagnosis of appendicitis; may obscure signs of overdose. Side/adverse effects: No confusion; sedative effects and gastrointestinal upset are more pronounced; thickening of mucus less pronounced. Additional Dosing Information See also General Dosing Information . When diphenhydramine is used for prophylaxis of motion sickness, it should be taken at least 30 minutes, and preferably 1 or 2 hours, before exposure to conditions that may precipitate motion sickness. Oral Dosage Forms DIPHENHYDRAMINE HYDROCHLORIDE CAPSULES USP Usual adult and adolescent dose Antihistaminic (H 1 -receptor) Oral, 25 to 50 mg every four to six hours as needed. Antidyskinetic 1 For idiopathic and postencephalitic parkinsonism: Oral, 25 mg three times a day initially, the dose then being gradually increased to 50 mg four times a day if needed. Antiemetic or Antivertigo agent Oral, 25 to 50 mg every four to six hours as needed. Sedative-hypnotic Oral, 50 mg twenty to thirty minutes before bedtime if needed. Usual adult prescribing limits Up to 300 mg daily. Usual pediatric dose Antihistaminic (H 1 -receptor) Children up to 6 years of age: Oral, 6.25 to 12.5 mg every four to six hours. Children 6 to 12 years of age: Oral, 12.5 to 25 mg every four to six hours, not to exceed 150 mg per day. Antiemetic or Antivertigo agent Oral, 1 to 1.5 mg per kg of body weight every four to six hours as needed, not to exceed 300 mg per day. Note: The available strength of the capsule may not conform to some of the recommended pediatric dosages. Usual geriatric dose See Usual adult and adolescent dose . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 25 mg (Rx)[Generic] 25 mg (OTC) [ Banophen ] [ Benadryl Allergy ] [ Genahist ] [ Nytol QuickCaps ][Generic] 50 mg (Rx)[Generic] 50 mg (OTC) [ Nytol QuickGels ] [ Sleep-eze D Extra Strength ] [ Unisom SleepGels Maximum Strength ][Generic] Canada— 25 mg (Rx) [ Allerdryl ] 25 mg (OTC) [ Benadryl ] 50 mg (Rx) [ Allerdryl ] 50 mg (OTC) [ Benadryl ] Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a tight container. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. DIPHENHYDRAMINE HYDROCHLORIDE ELIXIR USP Usual adult and adolescent dose See Diphenhydramine Hydrochloride Capsules USP . Usual adult prescribing limits See Diphenhydramine Hydrochloride Capsules USP . Usual pediatric dose Antihistaminic (H 1 -receptor) Oral, 1.25 mg per kg of body weight or 37.5 mg per square meter of body surface, every four to six hours, not to exceed 300 mg a day or for • Children weighing up to 9.1 kg: Oral, 6.25 to 12.5 mg every four to six hours. • Children weighing 9.1 kg and over: Oral, 12.5 to 25 mg every four to six hours. Antiemetic or Antivertigo agent Oral, 1 to 1.5 mg per kg of body weight every four to six hours as needed, not to exceed 300 mg per day. Antitussive Children up to 2 years of age: Dosage must be individualized by physician. Children 2 to 6 years of age: Oral, 6.25 mg every four to six hours as needed, not to exceed 25 mg per day. Children 6 to 12 years of age: Oral, 12.5 mg every four to six hours as needed, not to exceed 75 mg per day. Note: Premature and full-term neonates—Use is not recommended. Usual geriatric dose See Usual adult and adolescent dose . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 12.5 mg per 5 mL (Rx)[Generic] 12.5 mg per 5 mL (OTC) [ Diphen Cough (alcohol 5%)] [ Diphenhist ] [ Genahist (alcohol 14%)] [ Siladryl (alcohol 5.6%)][Generic] Canada— 12.5 mg per 5 mL (OTC) [ Benadryl (alcohol 14%)] Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a tight container. Protect from light. Protect from freezing. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. • Keep container tightly closed. DIPHENHYDRAMINE HYDROCHLORIDE TABLETS Usual adult and adolescent dose See Diphenhydramine Hydrochloride Capsules USP . Usual adult prescribing limits See Diphenhydramine Hydrochloride Capsules USP . Usual pediatric dose See Diphenhydramine Hydrochloride Elixir USP . Usual geriatric dose See Diphenhydramine Hydrochloride Capsules USP . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 25 mg (Rx)[Generic] 25 mg (OTC) [ Aller-med ] [ Banophen Caplets ] [ Benadryl ] [ Diphenhist Captabs ] [ Nervine Nighttime Sleep-Aid ] [ Sleep-Eze D ] [ Sominex ] 50 mg (Rx)[Generic] 50 mg (OTC) [ AllerMax Caplets ] [ Compoz ] [ Dormarex 2 ] [ Sleep-Eze D Extra Strength ] [ Twilite Caplets ] Canada— Not commercially available. Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), in a well-closed container, unless otherwise specified by manufacturer. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. Parenteral Dosage Forms DIPHENHYDRAMINE HYDROCHLORIDE INJECTION USP Usual adult and adolescent dose Antihistaminic (H 1 -receptor) or Antidyskinetic 1 Intramuscular or intravenous, 10 to 50 mg. Antiemetic or Antivertigo agent Intramuscular or intravenous, 10 mg initially, may be increased to 20 to 50 mg every two to three hours. Usual adult prescribing limits Up to 100 mg per dose or 400 mg daily. Usual pediatric dose Antihistaminic (H 1 -receptor) or Antidyskinetic Intramuscular, 1.25 mg per kg of body weight or 37.5 mg per square meter of body surface, four times a day, not to exceed 300 mg per day. Antiemetic or Antivertigo agent Intramuscular, 1 to 1.5 mg per kg of body weight every six hours, not to exceed 300 mg per day. Note: Premature and full-term neonates—Use is not recommended. Usual geriatric dose See Usual adult and adolescent dose . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 10 mg per mL (Rx)[Generic] 50 mg per mL (Rx) [ Benadryl ] [ Hyrexin ][Generic] Canada— 50 mg per mL (Rx) [ Benadryl ][Generic] Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Protect from light. Protect from freezing. DOXYLAMINE Summary of Differences Category: Also indicated as a sedative-hypnotic. Pharmacology/pharmacokinetics: Chemical group—Ethanolamine derivative. pKa—5.8 and 9.3. Other actions/effects—Greater anticholinergic activity. Duration of action—6 to 8 hours. Precautions: Drug interactions and/or related problems: May decrease emetic response to apomorphine. Oral Dosage Forms DOXYLAMINE SUCCINATE TABLETS USP Usual adult and adolescent dose Antihistaminic (H 1 -receptor) Oral, 12.5 to 25 mg every four to six hours as needed. Sedative-hypnotic Oral, 25 mg thirty minutes before bedtime if needed. Usual adult prescribing limits Up to 150 mg daily. Usual pediatric dose Antihistaminic (H 1 -receptor) Children up to 6 years of age: Use is not recommended. Children 6 to 12 years of age: Oral, 6.25 to 12.5 mg every four to six hours as needed. Sedative-hypnotic Use is not recommended. Usual geriatric dose See Usual adult and adolescent dose . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 25 mg (OTC) [ Unisom Nighttime Sleep Aid (scored)] Canada— Not commercially available. Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a well-closed container. Protect from light. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. FEXOFENADINE Summary of Differences Pharmacology/pharmacokinetics: Chemical group—Metabolite of terfenadine {49} Half-life—14.4 hours. {49} Time to peak concentration— 2.6 hours {49} . Oral Dosage Forms FEXOFENADINE HYDROCHLORIDE CAPSULES Usual adult and adolescent dose Antihistaminic (H 1 -receptor) Oral, 60 mg twice daily, or 180 mg once daily. {49} {50} Urticaria, chronic idiopathic 1 Oral, 60 mg twice daily. {49} {50} Note: For patients with decreased renal function, an initial dose of 60 mg once a day is recommended {49} {50} . Usual pediatric dose Antihistaminic (H 1 -receptor) Urticaria (treatment) 1 Children 12 years of age and older: See Usual adult and adolescent dose Children 6 to 11 years of age: Oral, 30 mg twice daily. {49} {50} Note: Capsules are not available in a 30 mg dose. Children up to 6 years of age: Safety and efficacy have not been established. {49} Note: In Canada, not indicated for children younger than 12 years of age {50} Note: For pediatric patients with decreased renal function, an initial dose of 30 mg once a day is recommended {49} {50} Strength(s) usually available U.S.— 60 mg (Rx) [ Allegra (croscarmellose sodium) ( magnesium stearate) (gelatin) ( lactose) (microcrystalline cellulose) (pregelatinized starch)] {49} Canada— 60 mg (Rx) [ Allegra ] Packaging and storage: Store at controlled room temperature 20– 25°C (68– 77 °F), preferably between 15 and 30 °C (59 and 86 °F). Protect from excessive moisture. {49} {50} FEXOFENADINE HYDROCHLORIDE TABLETS Usual adult and adolescent dose Antihistaminic (H 1 -receptor) Urticaria (treatment) 1 See Fexofenadine Hydrochloride Capsules {49} {50} Usual pediatric dose Antihistaminic (H 1 -receptor) Urticaria (treatment) 1 See Fexofenadine Hydrochloride Capsules Note: In Canada, not indicated for children younger than 12 years of age {49} {50} Strength(s) usually available U.S.— 30 mg (Rx) [ Allegra (croscarmellose sodium) ( magnesium stearate) (microcrystalline cellulose ) (pregelatinized starch)] {49} 60 mg (Rx) [ Allegra (croscarmellose sodium) ( magnesium stearate) (microcrystalline cellulose ) (pregelatinized starch)] {49} 180 mg (Rx) [ Allegra (croscarmellose sodium) ( magnesium stearate) (microcrystalline cellulose ) (pregelatinized starch)] {49} Canada— 60 mg (Rx) [ Allegra (croscarmellose sodium) ( hydroxypropyl methylcellulose) (iron oxide) (lactose) (magnesium stearate) (microcrystalline cellulose) (povidone ) (polyethylene glycol) ( silicon dioxide) (starch) ( titanium dioxide)] {50} Packaging and storage: Store at controlled room temperature 20– 25°C (68– 77 °F), preferably between 15 and 30 °C (59 and 86 °F). Protect from excessive moisture. {49} {50} HYDROXYZINE Summary of Differences Category: Also indicated in the treatment of anxiety and psychosis-related tension; antiemetic agent and sedative-hypnotic. Pharmacology/pharmacokinetics: Chemical group—Piperazine derivative. pKa—Hydroxyzine hydrochloride: 2.6 and 7. Half-life (elimination)—20 to 25 hours. Duration of action—4 to 6 hours. Precautions: Pregnancy—Not taking during early months of pregnancy because of fetal abnormalities in studies in animals. Drug interactions and/or related problems—May decrease emetic response to apomorphine. Laboratory value alterations—False increases in urine 17-hydroxycorticosteroid determinations. Medical considerations/contraindications—May impede diagnosis of appendicitis; may obscure signs of overdose. Side/adverse effects: No dizziness; no paradoxical reaction. Oral Dosage Forms HYDROXYZINE HYDROCHLORIDE CAPSULES Usual adult and adolescent dose Antianxiety agent or Sedative-hypnotic Oral, 50 to 100 mg as a single dose. Antihistaminic (H 1 -receptor) or Antiemetic Oral, 25 to 100 mg three or four times a day as needed. Usual pediatric dose Antianxiety agent or Sedative-hypnotic Oral, 600 mcg (0.6 mg) per kg of body weight as a single dose. Antihistaminic (H 1 -receptor) or Antiemetic Oral, 500 mcg (0.5 mg) per kg of body weight or 15 mg per square meter of body surface every six hours as needed; or for Children up to 6 years of age: Oral, 30 to 50 mg a day in divided doses, or 12.5 mg every six hours as needed. Children 6 to 12 years of age: Oral, 50 to 100 mg a day in divided doses, or 12.5 to 25 mg every six hours as needed. Usual geriatric dose See Usual adult and adolescent dose . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— Not commercially available. Canada— 10 mg (Rx) [ Apo-Hydroxyzine ] [ Novo-Hydroxyzin ] 25 mg (Rx) [ Apo-Hydroxyzine ] [ Atarax ] [ Multipax ] [ Novo-Hydroxyzin ] 50 mg (Rx) [ Apo-Hydroxyzine ] [ Multipax ] [ Novo-Hydroxyzin ] Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. HYDROXYZINE HYDROCHLORIDE SYRUP USP Usual adult and adolescent dose See Hydroxyzine Hydrochloride Capsules . Usual pediatric dose See Hydroxyzine Hydrochloride Capsules . Usual geriatric dose See Hydroxyzine Hydrochloride Capsules . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 10 mg per 5 mL (Rx) [ Atarax (alcohol 0.5%)][Generic] Canada— 10 mg per 5 mL (Rx) [ Atarax ] Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a tight, light-resistant container. Protect from freezing. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. HYDROXYZINE HYDROCHLORIDE TABLETS USP Usual adult and adolescent dose See Hydroxyzine Hydrochloride Capsules . Usual pediatric dose See Hydroxyzine Hydrochloride Capsules . Usual geriatric dose See Hydroxyzine Hydrochloride Capsules . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 10 mg (Rx) [ Atarax ][Generic] 25 mg (Rx) [ Atarax ][Generic] 50 mg (Rx) [ Atarax ][Generic] 100 mg (Rx) [ Atarax ][Generic] Canada— Not commercially available. Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a tight container. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. HYDROXYZINE PAMOATE CAPSULES USP Usual adult and adolescent dose Antianxiety agent or Sedative-hypnotic Oral, 50 to 100 mg as a single dose. Antihistaminic (H 1 -receptor) or Antiemetic Oral, 25 to 100 mg three to four times a day as needed. Usual pediatric dose Antianxiety agent or Sedative-hypnotic Oral, 600 mcg (0.6 mg) per kg of body weight as a single dose. Antihistaminic (H 1 -receptor) or Antiemetic Oral, 500 mcg (0.5 mg) per kg of body weight or 15 mg per square meter of body surface every six hours as needed; or for Children 6 years of age and over: Oral, 12.5 to 25 mg every six hours as needed. Usual geriatric dose See Usual adult and adolescent dose . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— The equivalent of hydroxyzine hydrochloride 25 mg (Rx) [ Vistaril ][Generic] 50 mg (Rx) [ Vistaril ][Generic] 100 mg (Rx) [ Vistaril ][Generic] Canada— Not commercially available. Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), in a well-closed container, unless otherwise specified by manufacturer. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. HYDROXYZINE PAMOATE ORAL SUSPENSION USP Usual adult and adolescent dose See Hydroxyzine Pamoate Capsules USP . Usual pediatric dose Antianxiety agent or Sedative-hypnotic Oral, 600 mcg (0.6 mg) per kg of body weight as a single dose. Antihistaminic (H 1 -receptor) or Antiemetic Oral, 500 mcg (0.5 mg) per kg of body weight or 15 mg per square meter of body surface every six hours as needed; or for Children up to 6 years of age: Oral, 12.5 mg every six hours as needed. Children 6 years of age and over: Oral, 12.5 to 25 mg every six hours as needed. Usual geriatric dose See Hydroxyzine Pamoate Capsules USP . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— The equivalent of hydroxyzine hydrochloride 25 mg per 5 mL (Rx) [ Vistaril ] Canada— Not commercially available. Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a tight, light-resistant container. Protect from freezing. Auxiliary labeling: • Shake well. • May cause drowsiness. • Avoid alcoholic beverages. Parenteral Dosage Forms HYDROXYZINE HYDROCHLORIDE INJECTION USP Usual adult and adolescent dose Antianxiety agent Intramuscular, 50 to 100 mg, repeated as needed every four to six hours. Sedative-hypnotic Intramuscular, 50 mg as a single dose. Adjunct to narcotic medication: Intramuscular, 25 to 100 mg. Antiemetic Intramuscular, 25 to 100 mg. Usual pediatric dose Adjunct to narcotic medication or Antiemetic Intramuscular, 1 mg per kg of body weight, or 30 mg per square meter of body surface, as a single dose. Usual geriatric dose See Usual adult and adolescent dose . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 25 mg per mL (Rx) [ Vistaril ][Generic] 50 mg per mL (Rx) [ Hyzine-50 ] [ Vistaril ][Generic] Canada— 50 mg per mL (Rx) [ Atarax ][Generic] Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Protect from light. Protect from freezing. LORATADINE Summary of Differences Indications: Used as treatment adjunct in asthma. Pharmacology/pharmacokinetics: Chemical group—Piperidine derivative. Other actions/effects—No significant anticholinergic activity. Mild bronchodilator. Protein binding—97%. Half-life—3 to 20 hours. Onset of action—Histamine skin wheal studies—1 to 3 hours. Time to peak concentration—1 to 2 hours. Time to peak effect—Histamine skin wheal studies—8 to 12 hours. Duration of action—Histamine skin wheal studies—At least 24 hours. Side/adverse effects: No paradoxical reaction; sedation more pronounced with large doses. Oral Dosage Forms LORATADINE SYRUP Usual adult and adolescent dose Antihistaminic (H 1 -receptor)—Oral, 10 mg once a day {03} . Note: In patients with hepatic failure or decreased renal function (creatinine clearance < 30 mL per minute), the initial dose should be 10 mg every other day {03} . Usual pediatric dose Antihistaminic (H 1 -receptor) Children 2 to 6 years of age: Oral, 5 mg once a day. Children 6 years of age and over: See Usual adult and adolescent dose {03} . Usual geriatric dose See Usual adult and adolescent dose . Strength(s) usually available U.S.— 5 mg per 5 mL (OTC) [ Claritin ] Canada— 5 mg per 5 mL (OTC) [ Claritin ] Packaging and storage: Store between 2 and 30 °C (36 and 86 °F), in a well-closed container, unless otherwise specified by manufacturer. LORATADINE TABLETS Usual adult and adolescent dose See Loratadine Syrup . Usual pediatric dose See Loratadine Syrup . Usual geriatric dose See Loratadine Syrup . Strength(s) usually available U.S.— 10 mg (OTC) [ Claritin (scored)] [ Claritin RediTabs (rapidly-disintegrating )] 10 mg (OTC) [ Alavert (orally disintegrating)] Canada— 10 mg (OTC) [ Claritin (scored)] Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), in a well-closed container, unless otherwise specified by manufacturer. PHENINDAMINE Summary of Differences Pharmacology/pharmacokinetics: Chemical group—Piperidine derivative. Duration of action—4 to 6 hours. Oral Dosage Forms PHENINDAMINE TARTRATE TABLETS Usual adult and adolescent dose Antihistaminic (H 1 -receptor) Oral, 25 mg every four to six hours as needed. Usual adult prescribing limits Up to 150 mg daily. Usual pediatric dose Antihistaminic (H 1 -receptor) Children up to 6 years of age: Dosage must be individualized by physician. Children 6 to 12 years of age: Oral, 12.5 mg every four to six hours as needed, not to exceed 75 mg per day. Children 12 years of age and over: See Usual adult and adolescent dose . Usual geriatric dose See Usual adult and adolescent dose . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 25 mg (OTC) [ Nolahist (scored)] Canada— Not commercially available. Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), in a well-closed container, unless otherwise specified by manufacturer. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. TRIPELENNAMINE Summary of Differences Pharmacology/pharmacokinetics: Chemical group—Ethylenediamine derivative. pKa—3.9 and 9. Duration of action—4 to 6 hours. Side/adverse effects: Gastrointestinal effects more pronounced; no dizziness. Oral Dosage Forms TRIPELENNAMINE CITRATE ELIXIR USP Usual adult and adolescent dose Antihistaminic (H 1 -receptor) Oral, the equivalent of tripelennamine hydrochloride: 25 to 50 mg every four to six hours as needed. Usual adult prescribing limits Up to the equivalent of 600 mg of tripelennamine hydrochloride daily. Usual pediatric dose Antihistaminic (H 1 -receptor) Oral, the equivalent of tripelennamine hydrochloride, 1.25 mg per kg of body weight or 37.5 mg per square meter of body surface every six hours as needed, not to exceed 300 mg per day. Note: Premature and full-term neonates—Use is not recommended. Usual geriatric dose See Usual adult and adolescent dose . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 37.5 mg of tripelennamine citrate (equivalent to 25 mg of tripelennamine hydrochloride) per 5 mL (Rx) [ PBZ (alcohol 12%)] Canada— Not commercially available. Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a tight, light-resistant container. Protect from freezing. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. • Keep container tightly closed. TRIPELENNAMINE HYDROCHLORIDE TABLETS USP Usual adult and adolescent dose Antihistaminic (H 1 -receptor)—Oral, 25 to 50 mg every four to six hours as needed. Usual adult prescribing limits Up to 600 mg daily. Usual pediatric dose Antihistaminic (H 1 -receptor)—Oral, 1.25 mg per kg of body weight or 37.5 mg per square meter of body surface every six hours as needed, not to exceed 300 mg per day. Note: Premature and full-term neonates—Use is not recommended. Usual geriatric dose See Usual adult and adolescent dose . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 25 mg (Rx) [ PBZ (scored)] 50 mg (Rx) [ PBZ (scored)] [ Pelamine (scored)][Generic] Canada— 50 mg (OTC) [ Pyribenzamine (scored)] Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a well-closed container. Auxiliary labeling: • May cause drowsiness. • Avoid alcoholic beverages. TRIPELENNAMINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS Usual adult and adolescent dose Antihistaminic (H 1 -receptor)—Oral, 100 mg every eight to twelve hours as needed. Usual adult prescribing limits Up to 600 mg daily. Usual pediatric dose Use is not recommended. Usual geriatric dose See Usual adult and adolescent dose . Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. Strength(s) usually available U.S.— 100 mg (Rx) [ PBZ-SR ] Canada— Not commercially available. Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), in a well-closed container, unless otherwise specified by manufacturer. Protect from light. Auxiliary labeling: • Swallow tablets whole. • May cause drowsiness. • Avoid alcoholic beverages. Revised: 03/03/2003 References Note: References used in the development and subsequent revisions of this monograph have not been incorporated into the database and therefore are not listed below. Cetirizine product monograph (Zyrtec, Pfizer—US), Rev 9/96. Product Information: Periactin®, cyproheptadine hydrochloride. Merck & Co, West Point, PA, (PI revised 9/1999) reviewed 10/2000. Product Information: Claratin®, loratadine tablets, syrup, and rapidly-disintegrating tablets. Schering, Kenilworth, NJ (PI revised 1/99) reviewed 6/2000. Astemizole package insert (Hismanal, Janssen—US), Rev 2/98, Rec 4/99. Reviewers' responses on monograph revision of 11/16/93. Tyolathi J, Lathi A. Start and end of effects of terfenadine and astemizole on histamine-induced wheals in human skin. Acta Derm Venereol (Stockholm) 1989; 69: 269-71. Davies R, Brook M, Griffiths J. Skin test recovery after astemizole therapy [abstract]. Rev Esp Alergol Immunol Clin 1987; 2: 79. Terfenadine product labeling, (Seldane, Hoechst Marion Roussel—US), Rev 9/97, Rec 2/98. Hedrick CL. DIAS Rounds. Astemizole effects on skin testing [letter]. Ann Pharmacother 1992; 26: 1389. Dimenhydrinate product labeling (Dramamine, Upjohn—US). Reviewers' responses on monograph revision of 1/28/91. Dexchlorpheniramine package insert (Polaramine repetabs, Schering—US), Rev 1/91, Rec 4/99. Davies BH. Prophylactic treatment of seasonal allergic rhinitis. Clin Ther 1991; 13: 87-91. Simons FE, Simons KJ. Second-generation H1-receptor antagonists. Ann Allergy 1991; 66: 5-15. West S, Brandon B, Stolley P, et al. A review of antihistamines and the common cold. Pediatr 1975; 56: 100-7. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513. Ricci AR, Settipane RJ, Goldstein BM, et al. The effect of chlorpheniramine in asthma. Allergy Proc1990; 11(5): 229-22. Rafferty P. Antihistamines in the treatment of clinical asthma. J Allergy Clin Immunol 1990; 46: 647-50. Howarth PH. Histamine and asthma: an appraisal based on specific H1-receptor antagonism. Clin Exp Allergy 1990; 20 Suppl 2: 31-41. Dirksen A, Engel T, Frülund L, et al. Effect of a non-sedative antihistamine (loratadine) in moderate asthma. A double-blind controlled clinical crossover trial. Allergy 1989; 44: 556-71. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 4th ed. Baltimore: Williams & Wilkins. 1994. Reviewers' responses to Allergy and Immunology Panel Ballot, 7/8/92. Brown MW, Maldonado AL, Meredith CG, et al. Effect of ketoconazole on hepatic oxidative drug metabolism. Clin Pharmacol Ther 1985; 37: 290-7. Itraconazole package insert (Sporonox, Janssen—US), Rev 1992. FDA talk paper. Important new safety information about Hismanal. Rockville, MD: Food and Drug Administration; February 1998. Report No.: T98-5. Cetirizine package insert (Zyrtec, Pfizer—US), Rev 1/97, Rec 4/99. Dimenhydrinate product monograph (Gravol, Carter-Horner—Canada), Rev 8/97, Rec 1/98. Gillis MC, editor. CPS Compendium of pharmaceuticals and specialties. 33rd ed. Ottawa: Canadian Pharmacists Association; 1998. p. 1920-1. Gillis MC, editor. CPS Compendium of pharmaceuticals and specialties. 33rd ed. Ottawa: Canadian Pharmacists Association; 1998. p. 1421-2. Gillis MC, editor. CPS Compendium of pharmaceuticals and specialties. 33rd ed. Ottawa: Canadian Pharmacists Association; 1998. p. 677. Dimenhydrinate. In: Drug topics red book 1998. Montvale, NJ: Medical Economics Company; 1998. p. 696. Gillis MC, editor. CPS Compendium of pharmaceuticals and specialties. 33rd ed. Ottawa: Canadian Pharmacists Association; 1998. p. 1323-4. Hydroxyzine package insert (Atarax, Pfizer—US), Rev 12/93, Rec 4/99. Gillis MC, editor. CPS Compendium of pharmaceuticals and specialties. 33rd ed. Ottawa: Canadian Pharmacists Association; 1998. p. 706-7. Gillis MC, editor. CPS Compendium of pharmaceuticals and specialties. 33rd ed. Ottawa: Canadian Pharmacists Association; 1998. p. 1219. Gillis MC, editor. CPS Compendium of pharmaceuticals and specialties. 33rd ed. Ottawa: Canadian Pharmacists Association; 1998. p. 500. Gillis MC, editor. CPS Compendium of pharmaceuticals and specialties. 33rd ed. Ottawa: Canadian Pharmacists Association; 1998. p. 1297-8. Gillis MC, editor. CPS Compendium of pharmaceuticals and specialties. 33rd ed. Ottawa: Canadian Pharmacists Association; 1998. p. 308-9. Gillis MC, editor. CPS Compendium of pharmaceuticals and specialties. 33rd ed. Ottawa: Canadian Pharmacists Association; 1998. p. 1633. Gillis MC, editor. CPS Compendium of pharmaceuticals and specialties. 33rd ed. Ottawa: Canadian Pharmacists Association; 1998. p. 182. Gillis MC, editor. CPS Compendium of pharmaceuticals and specialties. 33rd ed. Ottawa: Canadian Pharmacists Association; 1998. p. 326-7. Gillis MC, editor. CPS Compendium of pharmaceuticals and specialties. 33rd ed. Ottawa: Canadian Pharmacists Association; 1998. p. 1516-8. Gillis MC, editor. CPS Compendium of pharmaceuticals and specialties. 33rd ed. Ottawa: Canadian Pharmacists Association; 1998. p. 1406-7. Gillis MC, editor. CPS Compendium of pharmaceuticals and specialties. 33rd ed. Ottawa: Canadian Pharmacists Association; 1998. p. 150-1. Gillis MC, editor. CPS Compendium of pharmaceuticals and specialties. 33rd ed. Ottawa: Canadian Pharmacists Association; 1998. p. 1331. Product Information: Zyrtec®, cetirizine hydrochloride tablets and syrup. Pfizer Labs, New York, NY (PI revised 3/2000) reviewed 6/2000. Parfitt K, editor. Martindale: the extra pharmacopeia. 32nd ed. London: The Pharmaceutical Press; 1999. p. 402, 419. Product Information: Periactin®, cyproheptadine hydrochloride. Johnson & Johnson—Merck, Canada. Compendium of Pharmaceuticals and Specialties, 34th ed, Canadian Pharmacists Association, Ottawa, Ontario, Canada, 2000. p. 1215–6. Product Information: Allegra®, fexofenadine. Aventis Pharmaceuticals, Kansas City, MO. (PI revised 11/2000) PI reviewed 10/2001. Product Information: Allegra™, fexofenadine. Aventis Pharma, Laval, Quebec (PI revised 05/2000) PI reviewed 10/2001. Product Information: Clarinex®, desloratadine. Schering, Kenilworth, NJ, (PI issued 2/2002) reviewed 10/2002. Product Information: Aerius™, desloratadine. Schering Canada,.Pointe-Claire, Quebec, (PI revised 2/2002) reviewed 10/2002. Alavert™, loratadine. (12/20/2002). Wyeth. Retrieved February 26, 2003, from The World Wide Web: http://www.wyeth.com/news Printable Version Email Recommend Tweet Save or Share Search: Sign In or Register Username Password Forgot password? FDA Consumer Updates Primatene Mist With Chlorofluorocarbons No Longer Available After Dec. 31, 2011 HCG Diet Products are Illegal Lock it Up: Medicine Safety in Your Home Reducing Fever in Children: Safe Use of Acetaminophen More FDA Updates... Recently Approved Mitosol Mitosol (mitomycin) is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery. Sklice Sklice (ivermectin) Lotion is a pediculicide indicated for the topical treatment of head lice infestations in ... Jentadueto Jentadueto (linagliptin and metformin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide ... Kalydeco Kalydeco (ivacaftor) is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator  indicated ... Erivedge Erivedge (vismodegib) is a hedgehog pathway inhibitor for the treatment of patients with advanced basal cell ... More... Get Updates by Email Email me: FDA Medwatch Alerts News Roundup Daily Weekly Monthly Email Support About Drugs.com Your Privacy Advertise With Us Frequently Asked Questions Pharmaceutical Companies Widgets for your Website Content Submissions About Drugs.com Contact Us Sitemap Follow us on: Google+ Facebook Twitter Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines & natural products. This material is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment. Data sources include Micromedex™ (updated Jan 27th, 2011), Cerner Multum™ (updated Jan 3rd, 2012), Wolters Kluwer™ (updated Jan 31st, 2012) and  others. To view content sources and attributions, refer to our editorial policy . Copyright © 2000-2012 Drugs.com. All rights reserved. We comply with the HONcode standard for trustworthy health in